Literature DB >> 8500303

Quality control functions of the Visual Field Reading Center (VFRC) for the Optic Neuritis Treatment Trial (ONTT).

J L Keltner1, C A Johnson, R W Beck, P A Cleary, J O Spurr.   

Abstract

The Visual Field Reading Center (VFRC) was established to assess visual field testing in the Optic Neuritis Treatment Trial (ONTT), to train and certify ONTT technicians, and to monitor the quality of the visual fields through evaluation of the technical aspects of the visual field testing. We describe the functions of the VFRC personnel and the standardized test protocols developed by the VFRC for Humphrey and Goldmann perimetry. We also describe the VFRC procedures for training and certifying visual field technicians, double-checking the eligibility of ONTT patients, assessing the quality of the visual field data, and processing visual field data. In addition, we describe the principles applied by the director and associate director of the VFRC in their clinical classification of the various localized and diffuse visual field defects observed in the Humphrey and Goldmann visual fields. The VFRC has processed more than 14,000 Humphrey and Goldmann visual field tests. The visual field quality control procedures and visual field defect classification process have been shown to be quite reproducible. Through quality control assessment procedures, we have been able to pinpoint a variety of problems at an early stage and promptly implement corrective measures. The standardized test protocols, technician training and certification procedures, and quality control assessment techniques used by the VFRC for the ONTT may serve as a model for future clinical trials employing visual field data as an outcome measure. These procedures can also be used to enhance visual field reliability in ophthalmological practices.

Entities:  

Mesh:

Year:  1993        PMID: 8500303     DOI: 10.1016/0197-2456(93)90016-7

Source DB:  PubMed          Journal:  Control Clin Trials        ISSN: 0197-2456


  11 in total

1.  Clinical trial performance of community- vs university-based practices in the submacular surgery trials (SST): SST report no. 2.

Authors:  Neil M Bressler; Barbara S Hawkins; Susan B Bressler; Päivi H Miskala; Marta J Marsh
Journal:  Arch Ophthalmol       Date:  2004-06

2.  Visual field profile of optic neuritis: a final follow-up report from the optic neuritis treatment trial from baseline through 15 years.

Authors:  John L Keltner; Chris A Johnson; Kimberly E Cello; Mariya Dontchev; Robin L Gal; Roy W Beck
Journal:  Arch Ophthalmol       Date:  2010-03

3.  Baseline visual field findings in the Idiopathic Intracranial Hypertension Treatment Trial (IIHTT).

Authors:  John L Keltner; Chris A Johnson; Kimberly E Cello; Michael Wall
Journal:  Invest Ophthalmol Vis Sci       Date:  2014-04-29       Impact factor: 4.799

4.  Stratus OCT Quality Control in Two Multi-Centre Multiple Sclerosis Clinical Trials.

Authors:  John L Keltner; Kimberly E Cello; Laura J Balcer; Peter A Calabresi; Clyde E Markowitz; John S Werner
Journal:  Neuroophthalmology       Date:  2011-03-20

5.  Computerized expert system for evaluation of automated visual fields from the Ischemic Optic Neuropathy Decompression Trial: methods, baseline fields, and six-month longitudinal follow-up.

Authors:  Steven E Feldon
Journal:  Trans Am Ophthalmol Soc       Date:  2004

6.  Visual field defects in acute optic neuritis--distribution of different types of defect pattern, assessed with threshold-related supraliminal perimetry, ensuring high spatial resolution.

Authors:  J Nevalainen; E Krapp; J Paetzold; I Mildenberger; D Besch; R Vonthein; J L Keltner; C A Johnson; U Schiefer
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2008-02-01       Impact factor: 3.117

Review 7.  Visual fields in neuro-ophthalmology.

Authors:  Sachin Kedar; Deepta Ghate; James J Corbett
Journal:  Indian J Ophthalmol       Date:  2011 Mar-Apr       Impact factor: 1.848

8.  Development and validation of a computerized expert system for evaluation of automated visual fields from the Ischemic Optic Neuropathy Decompression Trial.

Authors:  Steven E Feldon; Lori Levin; Roberta W Scherer; Anthony Arnold; Sophia M Chung; Lenworth N Johnson; Gregory Kosmorsky; Steven A Newman; Joanne Katz; Patricia Langenberg; P David Wilson; Shalom E Kelman; Kay Dickersin
Journal:  BMC Ophthalmol       Date:  2006-11-20       Impact factor: 2.209

9.  Rituximab as a monotherapy or in combination therapy for the treatment of non-paraneoplastic autoimmune retinopathy.

Authors:  Arash Maleki; Neerav Lamba; Lina Ma; Stacey Lee; Alexander Schmidt; C Stephen Foster
Journal:  Clin Ophthalmol       Date:  2017-02-17

10.  Quality Control Procedures and Baseline Values for Electroretinography, Perimetry, Color Vision, and Visual Acuity in an International Multicenter Study: Observations from a Safety Trial in Chronic Stable Angina Pectoris.

Authors:  Eberhart Zrenner; Graham E Holder; Ulrich Schiefer; John M Wild
Journal:  Transl Vis Sci Technol       Date:  2020-07-28       Impact factor: 3.283

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.